David Simon on Trump FCPA Pause – 'That skill set remains critical'
February 24, 2025
Law.com
Foley & Lardner LLP partner David Simon commented in the Law.com article, “Trump’s Pause on FCPA Enforcement Triggers Doubts and Disappointment in Latin America,” sharing background on what the pause on new Foreign Corrupt Practices Act (FCPA) cases and review of existing investigations means for clients operating under its scope.
“FCPA lawyers have spent years guiding boards and executives through their most complex, high-risk crises—where financial, legal, and reputational risks all collide,” explained Simon, who is vice-chair of Foley’s Government Enforcement Defense & Investigations Practice. “That skill set remains critical.”
(Subscription required)
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.